Chembio to Present at Sidoti & Company, LLC 2013 Micro-Cap Conference

Chembio to Present at Sidoti & Company, LLC 2013 Micro-Cap Conference

MEDFORD, N.Y., Jan. 4, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests, today
announced that Lawrence Siebert, Chief Executive Officer of Chembio, will
present a corporate overview at the Sidoti & Company LLC's (www.sidoti.com)
2013 Micro-Cap Conference on Monday, January 7, 2013 at 2:10 p.m. Eastern
time. The conference will be held at the Grand Hyatt Hotel in New York City.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two U.S. Food and Drug Administration (FDA),
Pre-Market Approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by
Alere, Inc. (formerly, Inverness Medical Innovations, Inc.). Chembio markets
its HIV STAT-PAK^® line of rapid HIV tests internationally to government and
donor-funded programs directly and through distributors. Chembio has developed
a patented point-of-care test platform technology, the Dual Path Platform
(DPP^®) technology, which has significant advantages over lateral-flow
technologies. This technology is providing Chembio with a significant pipeline
of business opportunities for the development and manufacture of new products
based on DPP^®. Headquartered in Medford, NY, with approximately 170
employees, Chembio is licensed by the FDA as well as the U. S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485. For additional
information, please visit the Company's website at www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended. Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management. Such
statements, which are estimates only, reflect management's current views, are
based on certain assumptions, and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to Chembio's
ability to obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products. Chembio
undertakes no obligation to publicly update these forward-looking statements
to reflect events or circumstances that occur after the date hereof or to
reflect any change in Chembio's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events. Factors
that may impact Chembio's success are more fully disclosed in Chembio's most
recent public filings with the U.S. Securities and Exchange Commission.

CONTACT: Chembio Diagnostics
         Susan Norcott
         (631) 924-1135, ext. 125
         snorcott@chembio.com
        
         LHA
         Anne Marie Fields
         (212) 838-3777
         AFields@lhai.com
         @LHA_IR_PR
 
Press spacebar to pause and continue. Press esc to stop.